Avelumab - Merck KGaA
At a glance
- Drug Originator EMD Serono; Merck Biopharma; Merck KGaA
- Drug Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
- USA Patent Applicants EMD SERONO INC
- USA Patents 128
- BLAs 2
- International Patents 956

Disclaimer